Why Cochrane says standard check-ups don't work — and what does instead

If you've ever had an annual check-up, you probably assumed it was making you healthier. It's an intuitive assumption: more screening must catch more problems, which must lead to better outcomes. The problem is, the largest body of evidence we have says that's not true.

In 2019, the Cochrane Collaboration — the gold standard of evidence-based medicine — published a systematic review of general health checks. They pooled 17 randomized trials covering 251,891 adults. The results were striking.

General health checks did not reduce all-cause mortality. They did not reduce cardiovascular mortality. They did not reduce cancer mortality. What they did produce was more diagnoses — many of which reflected overdiagnosis rather than genuine health improvement.

"General health checks are unlikely to be beneficial." — Krogsbøll et al., Cochrane Database of Systematic Reviews, 2019

How can this be?

It seems counterintuitive. Surely finding problems early is better than finding them late. And for specific, targeted screenings, that's absolutely true. But general check-ups — the kind where a doctor orders a broad panel of tests without a clear clinical question — work differently than most people assume.

There are three main reasons.

1. The tests that matter are already targeted

Colonoscopy reduces colorectal cancer mortality by 68%. Statins reduce cardiovascular events by 22% per mmol/L of LDL-C reduction. Blood pressure treatment reduces events by 20% per 10mmHg reduction. These interventions work because they're precisely targeted at specific conditions in specific populations.

A general health check that throws a wide net rarely adds value to these already-proven targeted screenings. If you're 55, your targeted screenings are colonoscopy, lipid panel, and blood pressure. Adding twelve more tests doesn't improve your outcomes — it just increases the chance of a false alarm.

2. Overdiagnosis is a real harm

Overdiagnosis means finding a condition that would never have caused you problems. A common example is thyroid nodules: about 50% of adults have one, and more than 95% are benign and clinically silent. If you scan everyone's thyroid, you'll find lots of nodules, some of which will trigger biopsies, anxiety, surgeries, and lifelong medication — all for a condition that was never going to hurt them.

3. Asymptomatic ≠ healthy, but the signal-to-noise is low

When you screen 10,000 asymptomatic people for a condition that affects 100 of them, you need an extraordinarily accurate test to avoid drowning in false positives. Most screening tests aren't that accurate. The math doesn't work unless you stratify by risk first.

So what does work?

Preventive medicine is not useless — it's one of the most powerful tools we have. The Cochrane review doesn't say prevention is futile. It says untargeted prevention is futile. The fix is risk stratification: identifying who is actually at elevated risk for specific conditions, and applying proven interventions to those people.

The evidence for targeted preventive medicine is overwhelming:

• Colorectal cancer screening (colonoscopy or FIT from age 45): 68% mortality reduction. NNS ~1,250 over 10 years.
• Statin therapy for high cardiovascular risk: 22% event reduction per 1 mmol/L LDL-C lowered.
• Blood pressure treatment: 20% fewer cardiovascular events per 10mmHg lowered.
• Diabetes prevention through lifestyle (in prediabetics): 58% reduction in progression.
• Low-dose CT lung screening (high-risk smokers): 20% mortality reduction.
• Mammography (women 50–74): 20–30% breast cancer mortality reduction.

Every one of these works because it's applied to the right people at the right time. That's what evidence-based preventive medicine actually looks like.

What this means for Health Detectors

Our entire clinical program is built around this evidence. We don't run a "complete check-up" because the Cochrane review showed that doesn't help. Instead, we do something different:

First, we do DETECT, a focused risk assessment that combines 25+ evidence-graded biomarkers with a structured clinical history. This isn't a shotgun approach — every marker has a therapeutic consequence if it's abnormal.

Then, based on what DETECT shows, your physician recommends specific PROTECT modules. If your lipid panel and family history suggest elevated cardiovascular risk, you get cardiology with coronary calcium scoring. If it doesn't, you don't. If you're 50+ with no history, you get the colonoscopy that actually saves lives. If you have dense breast tissue, you get the supplemental ultrasound that actually finds cancers mammography misses.

What we don't do is offer tests that look impressive but lack evidence. You won't find routine whole-body MRI, NAD+ infusions, telomere panels, or testosterone therapy at normal levels in our program — because the evidence says these produce more harm than benefit.

The Cochrane review was a wake-up call for our field. It forced us to ask a harder question than "what can we measure?" The better question — the one our clinical program is built around — is: what will actually change your outcomes?